Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530

[1]  Zhengxin Wang,et al.  Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. , 2008, Cancer research.

[2]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[3]  J. Bjorge,et al.  PTP1B contributes to the oncogenic properties of colon cancer cells through Src activation. , 2007, Cancer research.

[4]  D. Kim,et al.  A hidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK Pathways , 2007, Oncogene.

[5]  H. Kung,et al.  Nonreceptor tyrosine kinases in prostate cancer. , 2007, Neoplasia.

[6]  C. Tepper,et al.  Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications. , 2006, Cancer research.

[7]  L. Otterbein,et al.  N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. , 2006, Journal of medicinal chemistry.

[8]  Zhiyong Guo,et al.  Regulation of androgen receptor activity by tyrosine phosphorylation. , 2006, Cancer cell.

[9]  Zijie Sun,et al.  Roles and regulation of Wnt signaling and β-catenin in prostate cancer , 2006 .

[10]  R. Nicholson,et al.  Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells , 2006, Breast Cancer Research and Treatment.

[11]  O. Gautschi,et al.  Clinical development of SRC tyrosine kinase inhibitors in lung cancer. , 2006, Clinical lung cancer.

[12]  C. Tepper,et al.  The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7 , 2006, Oncogene.

[13]  M. Planas-Silva,et al.  Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. , 2006, Biochemical and biophysical research communications.

[14]  J. Turkson,et al.  Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein , 2006, Molecular Cancer Therapeutics.

[15]  Sarah B. Tegen,et al.  Activated Src abrogates the Myc requirement for the G0/G1 transition but not for the G1/S transition. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Jin-Tang Dong.  Prevalent mutations in prostate cancer , 2006, Journal of cellular biochemistry.

[17]  Huan Yang,et al.  The Akt/PKB pathway: molecular target for cancer drug discovery , 2005, Oncogene.

[18]  J. Cheng,et al.  Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. , 2005, Cancer research.

[19]  D. Kalvakolanu,et al.  Down-Regulation of Signal Transducer and Activator of Transcription 3 Expression Using Vector-Based Small Interfering RNAs Suppresses Growth of Human Prostate Tumor In vivo , 2005, Clinical Cancer Research.

[20]  A. Traweger,et al.  Hyperosmotic mannitol induces Src kinase‐dependent phosphorylation of β‐catenin in cerebral endothelial cells , 2005, Journal of neuroscience research.

[21]  Y. Dor,et al.  Active Src Elevates the Expression of β-Catenin by Enhancement of Cap-Dependent Translation , 2005, Molecular and Cellular Biology.

[22]  L. Ellis,et al.  HIF-1α, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas , 2005, Oncogene.

[23]  J. Turkson,et al.  Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  W. Schulz,et al.  Effects of WNT/β-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines , 2005 .

[25]  Y. E. Chin,et al.  Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue , 2005, Science.

[26]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[27]  S. Courtneidge,et al.  The interplay between Src family kinases and receptor tyrosine kinases , 2004, Oncogene.

[28]  Shihua Sun,et al.  Changes in Androgen Receptor Nongenotropic Signaling Correlate with Transition of LNCaP Cells to Androgen Independence , 2004, Cancer Research.

[29]  A. Potti,et al.  Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. , 2004, Cancer.

[30]  R. Sears.  The Life Cycle of C-Myc: From Synthesis to Degradation , 2004, Cell cycle.

[31]  Timothy J. Yeatman,et al.  A renaissance for SRC , 2004, Nature Reviews Cancer.

[32]  D. Dominguez-Sola,et al.  PINning down the c-Myc oncoprotein , 2004, Nature Cell Biology.

[33]  H. Kung,et al.  Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK , 2004, Oncogene.

[34]  Hong Qian,et al.  Sensitivity and specificity amplification in signal transduction , 2003, Cell Biochemistry and Biophysics.

[35]  M. Rubin,et al.  β-Catenin-related Anomalies in Apoptosis-resistant and Hormone-refractory Prostate Cancer Cells , 2003 .

[36]  J. Parsons,et al.  Focal adhesion kinase: the first ten years , 2003, Journal of Cell Science.

[37]  D. Boschelli,et al.  SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. , 2003, Cancer research.

[38]  D. Schlaepfer,et al.  FRNK blocks v‐Src‐stimulated invasion and experimental metastases without effects on cell motility or growth , 2002, The EMBO journal.

[39]  P. Iversen,et al.  Inhibition of human chorionic gonadotropin β‐subunit modulates the mitogenic effect of c‐myc in human prostate cancer cells , 2002, The Prostate.

[40]  H. Frierson,et al.  Expression of focal adhesion kinase in normal and pathologic human prostate tissues , 2002, The Prostate.

[41]  Y. Daaka.  Mitogenic action of LPA in prostate. , 2002, Biochimica et biophysica acta.

[42]  Giulio Superti‐Furga,et al.  c‐Abl is an effector of Src for growth factor‐induced c‐myc expression and DNA synthesis , 2002, The EMBO journal.

[43]  H. Kung,et al.  Neuropeptide-Induced Androgen Independence in Prostate Cancer Cells: Roles of Nonreceptor Tyrosine Kinases Etk/Bmx, Src, and Focal Adhesion Kinase , 2001, Molecular and Cellular Biology.

[44]  M. Schaller.  Biochemical signals and biological responses elicited by the focal adhesion kinase. , 2001, Biochimica et biophysica acta.

[45]  T. Yeatman,et al.  Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[46]  D. Wechsler,et al.  Mxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cells , 2001, The Prostate.

[47]  J. Parsons,et al.  Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells , 2001, Oncogene.

[48]  S. Parsons,et al.  Tyrosine kinase signalling in breast cancer: Epidermal growth factor receptor and c-Src interactions in breast cancer , 2000, Breast Cancer Research.

[49]  H. Shih,et al.  Etk, a Btk Family Tyrosine Kinase, Mediates Cellular Transformation by Linking Src to STAT3 Activation , 2000, Molecular and Cellular Biology.

[50]  A. G. de Herreros,et al.  Regulation of E-cadherin/Catenin Association by Tyrosine Phosphorylation* , 1999, The Journal of Biological Chemistry.

[51]  P. Morin,et al.  β‐catenin signaling and cancer , 1999 .

[52]  Y. Hakak,et al.  Ubiquitin-dependent degradation of active Src , 1999, Current Biology.

[53]  M. Roussel,et al.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.

[54]  M. Steiner,et al.  Antisense c-myc retroviral vector suppresses established human prostate cancer. , 1998, Human gene therapy.

[55]  L. Zon,et al.  Induction of cyclin D1 by simian virus 40 small tumor antigen. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[56]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[57]  M. Barone,et al.  Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src , 1995, Nature.

[58]  C. Albanese,et al.  Transforming p21ras Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions (*) , 1995, The Journal of Biological Chemistry.

[59]  Y. Bang,et al.  Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[60]  S. Shurtleff,et al.  Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. , 1993, Genes & development.

[61]  C. Dinney,et al.  Metastatic model for human prostate cancer using orthotopic implantation in nude mice. , 1992, Journal of the National Cancer Institute.

[62]  E. Kohn,et al.  An autocrine motility factor secreted by the dunning R‐3327 rat prostatic adenocarcinoma cell subtype AT2.1 , 1991, International journal of cancer.

[63]  K. Mellström,et al.  Early activation of endogenous pp60src kinase activity during neuronal differentiation of cultured human neuroblastoma cells , 1990, Molecular and cellular biology.

[64]  Zijie Sun,et al.  Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. , 2006, Cancer letters.

[65]  W. Schulz,et al.  Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. , 2005, International journal of oncology.

[66]  M. Rubin,et al.  Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[67]  P. Morin,et al.  beta-catenin signaling and cancer. , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.

[68]  H. Kung,et al.  EtkyBmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3*-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells (cytokineysignal transductionyphosphatidylinositidesyLNCaP) , 1998 .